Abstract
20 untreated Hodgkin's disease patients and 1 patient relapsing after radiotherapy (17 stage IIB-IV and 4 stage I-IIA) were given doxorubicin, bleomycin, etoposide and prednisone on a 21-day cycle. The response rate was 95% and 16 patients (76%) achieved complete remission. 4 patients have relapsed 2, 5, 22 and 50 months after treatment. Survival was 100% at a median follow-up of 35 months. However, due to dyspnoea on exertion in 2 patients, bleomycin will be abandoned, and the occurrence of two second malignancies questions the role of etoposide as a leukaemogenic agent.
MeSH terms
-
Aclarubicin
-
Adolescent
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bleomycin / administration & dosage
-
Bleomycin / adverse effects
-
Cytarabine / analogs & derivatives
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Etoposide / administration & dosage
-
Etoposide / adverse effects
-
Female
-
Follow-Up Studies
-
Hodgkin Disease / drug therapy*
-
Hodgkin Disease / mortality
-
Humans
-
Leukemia, Myeloid, Acute / chemically induced
-
Male
-
Mechlorethamine / administration & dosage
-
Middle Aged
-
Myelodysplastic Syndromes / chemically induced
-
Neoplasms, Second Primary
-
Prednisolone
-
Prednisone / administration & dosage
-
Prednisone / adverse effects
-
Procarbazine / administration & dosage
-
Vincristine / administration & dosage
Substances
-
Cytarabine
-
Bleomycin
-
Procarbazine
-
Mechlorethamine
-
Vincristine
-
Etoposide
-
Aclarubicin
-
Doxorubicin
-
Prednisolone
-
Prednisone
Supplementary concepts
-
ABEP protocol 1
-
ABEP protocol 2
-
MOPP protocol